PDS0101 (Versamune®-HPV)
HPV16-positive Head and Neck Cancer (Recurrent/Metastatic)
Key Facts
About PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileAbout PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileAbout PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileAbout PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profile